Health In Tech, Inc. CFO and Director Qian LinLin filed a Form 4 on November 13, 2026, reporting seven separate restricted stock acquisitions totaling 3,050,000 shares of common stock on November 10, 2026, all at a price of $0.
Key Highlights
- Seven grants on one date: All transactions occurred on November 10, 2026, the date of Health In Tech's 2026 Annual Meeting of Stockholders.
- Total shares acquired: 3,050,000 shares across six Class A Common Stock grants (2,850,000 shares) and one Class B Common Stock grant (200,000 shares), each at $0 price.
- Post-transaction ownership: Following all reported transactions, Qian LinLin directly held 11,967,151 shares of Class A Common Stock and 2,900,000 shares of Class B Common Stock.
- Time-based vesting grant: 650,000 Class A shares vest in twelve equal monthly installments beginning November 15, 2026, subject to continued service.
- Market-cap performance conditions: Four grants totaling 1,600,000 Class A shares and 200,000 Class B shares are subject to market capitalization thresholds ranging from $150 million to $1 billion, measured by 10-day VWAP, with deadlines between April 30, 2028, and December 31, 2031.
- Acquisition-contingent grant: 800,000 Class A shares vest only upon the closing of an acquisition by the issuer on or before December 31, 2028, and are otherwise forfeited without consideration.
- Change in Control provision: According to the filing, all unvested restricted shares vest in full upon a Change in Control as defined in the Health In Tech, Inc. Equity Incentive Plan.
Qian LinLin Receives Restricted Stock Grants Tied to Service, Acquisition, and Market Milestones
According to the filing, Qian LinLin, who serves as Chief Financial Officer, Director, and 10% Owner of Health In Tech, Inc. (NASDAQ:HIT), acquired seven tranches of restricted shares on November 10, 2026. The grants were made under the Health In Tech, Inc. Equity Incentive Plan. One grant of 650,000 Class A shares was described as contingent upon stockholder approval of an amendment to the Plan, which was obtained at the issuer's 2026 Annual Meeting of Stockholders held that same day, per the filing's explanation of responses.
Four grants carry market capitalization performance conditions. The filing states that 600,000 Class A shares are forfeited unless the issuer's market capitalization, measured by 10-day VWAP, exceeds $150 million by April 30, 2028; a separate 600,000 Class A shares require a $300 million threshold by December 31, 2028; 200,000 Class A shares require $500 million by December 31, 2029; and 200,000 Class A shares require $1 billion by December 31, 2031. A matching 200,000 Class B shares were granted on the same $150 million market cap terms. For each of these performance grants, once the threshold is met, shares vest in twelve equal monthly installments subject to continued service, according to the filing.
The remaining 800,000 Class A shares vest only upon the closing of an acquisition by the issuer on or before December 31, 2028, and are otherwise forfeited without consideration, the filing stated. The filing noted that the post-transaction Class A tally of 11,967,151 shares includes 3,828,516 restricted shares and 8,138,635 unrestricted shares, and excludes 200,000 restricted Class B shares, 2,700,000 Class B shares, and 711,510 options to purchase Class A shares. The form was signed by Lori Babcock as attorney-in-fact for LinLin Qian on November 13, 2026.
What Was Disclosed
The filing reported seven restricted stock grants to Qian LinLin, CFO and Director of Health In Tech, Inc., on November 10, 2026, totaling 3,050,000 shares across Class A and Class B Common Stock, all acquired at $0, with vesting conditions tied to service, an acquisition event, and market capitalization milestones.



Please wait processing your request...